Biomerica, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMRA research report →
Price Chart
About the company
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications.
- CEO
- Zackary S. Irani
- IPO
- 1984
- Employees
- 50
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on BMRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.97M
- P/E
- -0.67
- Fwd P/E
- 3.38
- PEG
- 0.01
- P/S
- 1.17
- P/B
- 0.99
- EV/EBITDA
- -0.92
- Div Yield
- 0.00%
- Gross Margin
- 0.90%
- Op Margin
- -125.22%
- Net Margin
- -115.49%
- ROE
- -142.81%
- ROIC
- -90.91%
Latest fiscal year · YoY change
- Revenue
- $4.45M-16.2%
- Gross Profit
- $362.00K-27.3%
- Op Income
- $-5,320,000
- Net Income
- $-3,775,000+24.1%
- EPS
- $-1.30+39.8%
- OCF Growth
- +10.9%
- FCF Growth
- +11.8%
- 52W High
- $2.94
- 52W Low
- $1.01
- 50D MA
- $1.87
- 200D MA
- $1.97
- Beta
- 0.31
- RSI (14)
- 21
- Avg Volume
- 72.95K
No earnings-call transcripts are available for BMRA yet.
- Free Float
- 82.1%
- Shares Outstanding
- 4.60M
- Float Shares
- 3.78M
of shares held by institutions
21 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Hrt Financial LP | 34.78K | ▲ 8.40K |
| Vanguard Group Inc | 21.13K | 0 |
| Geode Capital Management, LLC | 19.34K | ▼ 5.01K |
| Blackrock, Inc. | 18.64K | 0 |
| Vanguard Capital Management LLC | 14.51K | 0 |
| State Street Corp | 13.05K | ▲ 13.05K |
| Susquehanna International Group, Llp | 12.18K | ▲ 12.18K |
| Citadel Advisors LLC | 12.07K | ▲ 12.07K |
| Texas Capital Bank Wealth Management Services Inc | 11.70K | ▲ 11.70K |
| Lpl Financial LLC | 10.85K | 0 |
| Vanguard Fiduciary Trust Co | 6.61K | 0 |
| Berthel, Fisher & Company Financial Services, Inc. | 5.05K | ▲ 705 |
Held by 6 ETFs
Biggest fund positions in BMRA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 25, 26 | BRC Group Holdings, Inc. | other | 0 |
| Aug 27, 26 | Qu Xiaoxuan | other | 0 |
| Aug 27, 26 | Qu Xiaoxuan | other | 0 |
| Aug 27, 26 | Qu Xiaoxuan | other | 0 |
| Aug 27, 26 | Qu Xiaoxuan | other | 0 |
| Aug 20, 26 | Gary M. Huff | buy | 31,250 |
| Aug 26, 26 | MOATAZEDI DAVID | buy | 10,000 |
| Aug 26, 26 | Chin Eric | buy | 6,250 |
| Aug 26, 26 | BARBIERI ALLEN | buy | 20,000 |
| Aug 26, 26 | Irani Zackary S. | buy | 31,250 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BMRA coverage
Recent articles, reports, and earnings notes.

Biomerica's $2.23 million financing is a runway warning, not a rescue
Biomerica's $2.23 million private placement adds shares while the FY2026 filing still carries going-concern language. With revenue down 16.2% and a $3.77 million net loss, the raise buys time but does not establish a turnaround.

Biomerica's new financing buys time, not a turnaround
Biomerica's $2.23 million financing extends its runway, but it adds roughly 30% to the pre-deal share count without proving the business is turning. With severe losses, negative cash flow, and the stock still below its 200-day average, BMRA remains a dilution trade rather than a turnaround.
Want a deeper read on BMRA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Biomerica Reports First Quarter Fiscal 2027 Financial Results
globenewswire.com · Oct 16
Head-To-Head Survey: Biomerica (NASDAQ:BMRA) versus Cytosorbents (NASDAQ:CTSO)
defenseworld.net · Sep 10
Biomerica Reports Fiscal 2026 Year-End Financial Results
globenewswire.com · Sep 1
Biomerica Announces $2.23 Million Financing
globenewswire.com · Aug 27
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
globenewswire.com · May 28
Biomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
globenewswire.com · Apr 29
Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
globenewswire.com · Apr 16
Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
globenewswire.com · Apr 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.